Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Irvine, CA, US. The stock last traded at $3.71, down 0.93% on the session, giving a market capitalisation of $286.8M. On trailing twelve-month figures it carries a trailing P/E of -4.27, a net margin of 0.0%. Its beta of 0.96 implies it has historically moved less than the broad market.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Eledon Pharmaceuticals, Inc. is most often compared with the following Healthcare names: